Complete Filing Data
Forte Biosciences, Inc. reported Net Income Loss of -$69.38 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Forte Biosciences, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$69.4M | -$35.5M | -$31.5M | -$13.9M | -$21.7M | -$46.5M | -$4.1M | -$49.0M | -$38.9M | -$33.5M | -$23.1M |
| Operating Expenses | $70.7M | $36.6M | $32.5M | $13.9M | $21.5M | $46.3M | $4.1M | $63.9M | $37.7M | $31.7M | $23.0M |
| Operating Income Loss | -$70.7M | -$36.6M | -$32.5M | -$13.9M | -$21.5M | -$46.3M | -$4.1M | -$45.9M | -$37.6M | -$31.7M | -$23.0M |
| General And Administrative Expense | $12.4M | $15.4M | $10.6M | $8.3M | $7.6M | $4.2M | $1.4M | $12.8M | $8.6M | $4.5M | $3.8M |
| Other Nonoperating Income Expense | -$396.0K | -$190.0K | -$114.0K | -$145.0K | -$222.0K | -$205.0K | -$5.0K | ||||
| Comprehensive Income Net Of Tax | -$69.4M | -$35.5M | -$31.5M | -$13.9M | -$63.5M | -$48.9M | -$39.0M | -$33.4M | -$23.1M | ||
| Research And Development Expense Excluding Acquired In Process Cost | $57.6M | $20.7M | $21.9M | $5.6M | $13.9M | $10.0M | $2.7M | ||||
| Research And Development Expense | $45.3M | $51.1M | $29.1M | $27.2M | $19.2M | ||||||
| Interest Expense Debt | $3.8M | $2.9M | $1.9M | $2.1M | $339.0K | ||||||
| Revenue From Contract With Customer Excluding Assessed Tax | $36.0K | $18.0M | $41.0K | $49.0K | |||||||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$8.0K | $7.0K | $4.0K | ||||||||
| Other Comprehensive Income Loss Net Of Tax | $33.0K | $11.0K | -$34.0K | $58.0K | -$52.0K | ||||||
| Deferred Revenue Current | $36.0K | $36.0K | $45.0K | ||||||||
| Nonoperating Income Expense | $2.3M | $1.1M | -$1.3M | -$1.8M | -$102.0K | ||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$68.3M | -$35.5M | -$63.5M | -$47.3M | -$38.9M | -$33.5M | |||||
| Research And Development For Related Party | $600.0K | $479.0K | |||||||||
| Income Tax Expense Benefit | $1.0M | $0.00 | $1.0K | $1.7M | $1.0K | $1.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 | Q3 2016 | Q2 2016 | Q1 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$17.7M | -$11.2M | -$15.7M | -$8.4M | -$12.5M | -$7.4M | -$10.0M | -$8.9M | -$6.8M | -$3.4M | -$3.0M | -$2.6M | -$7.8M | -$5.8M | -$4.8M | -$5.1M | -$34.8M | -$2.1M | -$10.6M | -$690.0K | -$630.0K | -$1.2M | -$19.6M | -$383.0K | -$16.1M | -$12.9M | -$10.8M | -$10.0M | -$9.1M | -$9.1M | -$8.4M | -$9.0M | -$8.0M | -$8.0M |
| Operating Expenses | $18.4M | $11.6M | $16.1M | $8.6M | $12.8M | $7.8M | $10.2M | $9.0M | $6.9M | $3.4M | $3.0M | $2.5M | $7.7M | $5.7M | $4.7M | $5.0M | $34.8M | $2.0M | $10.7M | $684.0K | $629.0K | $16.9M | $19.1M | $16.6M | $15.3M | $12.9M | $10.7M | $9.7M | $8.7M | $8.6M | $8.0M | $8.5M | $7.6M | $7.6M |
| Operating Income Loss | -$18.4M | -$11.6M | -$16.1M | -$8.6M | -$12.8M | -$7.8M | -$10.2M | -$9.0M | -$6.9M | -$3.4M | -$3.0M | -$2.5M | -$7.7M | -$5.7M | -$4.7M | -$5.0M | -$34.8M | -$2.0M | -$684.0K | -$629.0K | -$16.9M | $1.4M | -$15.3M | -$12.8M | -$9.7M | -$8.7M | -$8.6M | -$8.5M | -$7.6M | -$7.6M | ||||
| General And Administrative Expense | $3.2M | $3.0M | $3.4M | $2.8M | $7.1M | $3.5M | $3.8M | $1.9M | $2.1M | $2.0M | $2.0M | $1.8M | $2.0M | $2.2M | $1.4M | $1.3M | $760.0K | $673.0K | $331.0K | $319.0K | $4.4M | $4.3M | $2.6M | $2.4M | $2.2M | $2.0M | $1.9M | $956.0K | $1.1M | $1.1M | ||||
| Other Nonoperating Income Expense | $701.0K | $330.0K | $468.0K | $237.0K | $307.0K | $384.0K | $261.0K | $138.0K | $102.0K | $23.0K | -$15.0K | -$53.0K | -$52.0K | -$65.0K | -$63.0K | -$92.0K | -$7.0K | -$23.0K | -$6.0K | -$1.0K | -$213.0K | -$301.0K | -$762.0K | -$34.0K | ||||||||||
| Comprehensive Income Net Of Tax | -$17.7M | -$11.2M | -$15.7M | -$8.4M | -$12.5M | -$7.4M | -$10.0M | -$8.9M | -$6.8M | -$3.4M | -$3.0M | -$10.3M | -$18.7M | -$17.1M | -$17.0M | -$352.0K | -$16.0M | -$13.0M | -$9.9M | -$9.1M | -$9.1M | -$9.0M | -$8.0M | -$8.0M | ||||||||||
| Research And Development Expense Excluding Acquired In Process Cost | $15.1M | $8.5M | $12.5M | $5.7M | $5.6M | $4.3M | $6.4M | $7.1M | $4.8M | $1.4M | $1.0M | $693.0K | $5.7M | $3.5M | $3.3M | $3.7M | $1.9M | $1.4M | $353.0K | $310.0K | ||||||||||||||
| Research And Development Expense | $3.1M | $13.3M | $12.0M | $12.4M | $12.3M | $12.8M | $10.4M | $7.6M | $6.6M | $6.6M | $7.6M | $6.5M | $6.5M | |||||||||||||||||||||
| Interest Expense Debt | $756.0K | $2.0M | $764.0K | $754.0K | $742.0K | $1.1M | $349.0K | $430.0K | $495.0K | $616.0K | $511.0K | $505.0K | $503.0K | |||||||||||||||||||||
| Revenue From Contract With Customer Excluding Assessed Tax | $9.0K | $9.0K | $9.0K | $18.0M | $9.0K | $9.0K | $10.0K | $10.0K | ||||||||||||||||||||||||||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$6.0K | $0.00 | -$11.0K | $8.0K | -$5.0K | -$6.0K | -$6.0K | $1.0K | ||||||||||||||||||||||||||
| Other Comprehensive Income Loss Net Of Tax | -$10.0K | -$13.0K | $38.0K | $41.0K | $31.0K | $54.0K | -$74.0K | |||||||||||||||||||||||||||
| Deferred Revenue Current | $9.0K | $18.0K | $27.0K | $36.0K | $1.0M | $36.0K | $41.0K | $41.0K | $41.0K | |||||||||||||||||||||||||
| Nonoperating Income Expense | -$762.0K | -$34.0K | -$216.0K | -$414.0K | -$520.0K | -$469.0K | -$422.0K | -$440.0K | ||||||||||||||||||||||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$18.7M | $1.1M | -$10.0M | |||||||||||||||||||||||||||||||
| Research And Development For Related Party | $150.0K | $150.0K | $150.0K | $150.0K | $150.0K | $29.0K | ||||||||||||||||||||||||||||
| Income Tax Expense Benefit | $1.5M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $61.0M | $52.5M | $35.3M | $38.8M | $41.5M | $59.0M | -$4.8M | -$736.0K | $71.1M | -$124.4M | -$92.3M | -$70.4M |
| Cash And Cash Equivalents At Carrying Value | $77.0M | $22.2M | $37.1M | $41.1M | $42.0M | $58.8M | $6.9M | $35.9M | $5.5M | $8.2M | $4.2M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $77.0M | $22.2M | $37.1M | $41.1M | $42.0M | $58.8M | $6.9M | $5.0M | ||||
| Retained Earnings Accumulated Deficit | -$223.4M | -$154.0M | -$118.5M | -$87.0M | -$73.2M | -$51.5M | -$5.0M | -$215.9M | -$166.9M | -$128.0M | ||
| Prepaid Expense And Other Assets Current | $3.6M | $3.0M | $1.2M | $411.0K | $476.0K | $1.1M | $567.0K | $1.7M | $1.9M | $1.2M | ||
| Liabilities Current | $20.8M | $9.1M | $3.7M | $3.2M | $1.8M | $2.3M | $1.9M | $16.5M | $17.3M | $14.4M | ||
| Liabilities And Stockholders Equity | $82.8M | $61.6M | $39.0M | $42.0M | $43.3M | $61.2M | $7.7M | $103.1M | $92.1M | $35.4M | ||
| Common Stock Value | $13.0K | $6.0K | $1.0K | $21.0K | $15.0K | $13.0K | $2.0K | $23.0K | $20.0K | $2.0K | ||
| Assets Current | $80.6M | $61.3M | $38.3M | $41.5M | $42.5M | $59.9M | $7.5M | $97.7M | $90.6M | $32.5M | ||
| Assets | $82.8M | $61.6M | $39.0M | $42.0M | $43.3M | $61.2M | $7.7M | $103.1M | $92.1M | $35.4M | ||
| Additional Paid In Capital Common Stock | $284.3M | $206.5M | $153.8M | $125.8M | $114.7M | $110.4M | $199.0K | $274.0M | $238.0M | $3.6M | ||
| Accrued Liabilities Current | $10.8M | $4.2M | $2.2M | $2.0M | $812.0K | $1.0M | $343.0K | $13.1M | $8.1M | $5.4M | ||
| Accounts Payable Current | $10.0M | $4.9M | $1.4M | $1.2M | $946.0K | $1.2M | $1.6M | $3.4M | $2.0M | $1.7M | ||
| Unrealized Gain Loss On Investments | -$8.0K | $7.0K | $4.0K | $33.0K | $11.0K | -$34.0K | $58.0K | -$52.0K | ||||
| Other Assets Noncurrent | $2.1M | $138.0K | $544.0K | $486.0K | $786.0K | $1.2M | $0.00 | $1.4M | $227.0K | $2.1M | ||
| Property Plant And Equipment Net | $129.0K | $77.0K | $109.0K | $97.0K | $152.0K | $4.0M | $1.2M | $743.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $54.7M | -$14.9M | -$4.0M | -$944.0K | -$16.7M | $51.8M | $1.9M | $4.9M | $30.4M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $3.0K | $11.0K | $4.0K | -$23.0K | -$34.0K | |||||||
| Liabilities | $21.8M | $9.1M | $44.9M | $21.0M | $28.4M | |||||||
| Marketable Securities | $55.3M | $52.8M | $25.7M | |||||||||
| Repayments Of Notes Payable | $23.2M | $3.0M | $7.2M | $600.0K | ||||||||
| Accretion Amortization Of Discounts And Premiums Investments | $237.0K | $158.0K | $131.0K | -$161.0K | $248.0K | $19.0K | $9.0K | |||||
| Long Term Debt Noncurrent | $26.2M | $3.6M | $10.2M | |||||||||
| Cash And Cash Equivalents Period Increase Decrease | $4.9M | $30.4M | -$2.6M | $3.9M | ||||||||
| Notes Payable Current | $7.2M | $7.2M | ||||||||||
| Taxes Paid Related To Net Share Settlement Of Equity Awards | $29.0K | $35.0K | $60.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 | Q3 2016 | Q2 2016 | Q1 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $84.1M | $98.6M | $38.4M | $9.4M | $17.0M | $28.7M | $40.4M | $24.9M | $32.9M | $42.8M | $38.2M | $40.0M | $43.7M | $49.9M | $54.7M | $20.3M | $24.9M | -$6.8M | -$3.2M | -$2.5M | -$1.9M | $47.7M | $46.1M | $59.7M | $80.1M | $88.6M | -$132.9M | |||||
| Cash And Cash Equivalents At Carrying Value | $93.4M | $106.1M | $45.9M | $16.4M | $24.5M | $30.4M | $46.2M | $20.4M | $35.9M | $44.0M | $38.5M | $40.0M | $45.7M | $50.8M | $54.8M | $20.2M | $27.7M | $14.2M | $25.6M | $18.9M | $31.0M | $40.8M | $23.5M | $24.6M | $17.8M | $74.8M | $76.1M | $7.0M | $4.1M | $5.3M | $4.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $93.4M | $106.1M | $45.9M | $16.4M | $24.5M | $30.4M | $46.2M | $20.4M | $35.9M | $44.0M | $38.5M | $40.0M | $45.7M | $50.8M | $54.8M | $20.2M | $27.7M | $4.1M | $7.7M | $8.3M | ||||||||||||
| Retained Earnings Accumulated Deficit | -$198.6M | -$180.9M | -$169.7M | -$146.8M | -$138.5M | -$125.9M | -$112.6M | -$102.7M | -$93.8M | -$82.2M | -$78.8M | -$75.7M | -$69.8M | -$62.1M | -$56.3M | -$46.9M | -$41.8M | -$289.7M | -$268.8M | -$250.1M | -$233.0M | -$196.3M | -$195.9M | -$179.8M | -$156.1M | -$146.1M | -$137.1M | |||||
| Prepaid Expense And Other Assets Current | $2.0M | $1.5M | $1.3M | $1.3M | $1.2M | $1.1M | $917.0K | $322.0K | $369.0K | $546.0K | $298.0K | $376.0K | $891.0K | $1.1M | $1.1M | $1.4M | $395.0K | $277.0K | $4.2M | $4.5M | $1.6M | $5.2M | $4.0M | $3.1M | $1.2M | $953.0K | $1.2M | |||||
| Liabilities Current | $13.0M | $9.2M | $9.0M | $8.6M | $9.1M | $3.3M | $7.5M | $6.3M | $3.8M | $2.3M | $1.5M | $1.3M | $3.7M | $3.0M | $2.4M | $2.4M | $3.4M | $12.6M | $41.7M | $17.3M | $16.2M | $14.6M | $13.8M | $16.9M | $16.7M | $15.2M | $16.1M | |||||
| Liabilities And Stockholders Equity | $97.1M | $107.8M | $47.5M | $17.9M | $26.1M | $32.0M | $47.9M | $31.2M | $36.7M | $45.1M | $39.7M | $41.3M | $47.4M | $52.9M | $57.1M | $22.7M | $28.3M | $18.6M | $70.7M | $85.2M | $94.7M | $90.4M | $87.3M | $78.7M | $102.2M | $110.8M | $34.3M | |||||
| Common Stock Value | $13.0K | $12.0K | $6.0K | $1.0K | $36.0K | $36.0K | $36.0K | $21.0K | $21.0K | $21.0K | $15.0K | $15.0K | $15.0K | $14.0K | $13.0K | $11.0K | $11.0K | $23.0K | $23.0K | $23.0K | $23.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $2.0K | |||||
| Assets Current | $95.4M | $107.6M | $47.2M | $17.7M | $25.7M | $31.5M | $47.1M | $30.7M | $36.3M | $44.6M | $38.8M | $40.4M | $46.6M | $51.9M | $55.9M | $21.6M | $28.1M | $14.5M | $59.5M | $72.8M | $81.7M | $85.1M | $83.5M | $77.1M | $100.8M | $109.6M | $30.0M | |||||
| Assets | $97.1M | $107.8M | $47.5M | $17.9M | $26.1M | $32.0M | $47.9M | $31.2M | $36.7M | $45.1M | $39.7M | $41.3M | $47.4M | $52.9M | $57.1M | $22.7M | $28.3M | $18.6M | $70.7M | $85.2M | $94.7M | $90.4M | $87.3M | $78.7M | $102.2M | $110.8M | $34.3M | |||||
| Additional Paid In Capital Common Stock | $282.7M | $279.5M | $208.1M | $156.2M | $155.4M | $154.6M | $153.0M | $127.6M | $126.7M | $125.0M | $117.0M | $115.8M | $113.5M | $112.0M | $110.9M | $67.2M | $66.6M | $291.7M | $288.6M | $286.5M | $277.8M | $244.0M | $242.0M | $239.6M | $236.2M | $234.7M | $4.2M | |||||
| Accrued Liabilities Current | $7.5M | $3.9M | $4.0M | $3.4M | $3.8M | $1.6M | $2.1M | $3.3M | $2.4M | $1.1M | $815.0K | $680.0K | $1.4M | $2.0M | $1.2M | $898.0K | $866.0K | $6.0M | $11.6M | $10.4M | $11.2M | $10.0M | $11.2M | $7.9M | $8.3M | $6.7M | $7.9M | |||||
| Accounts Payable Current | $5.5M | $5.3M | $5.0M | $5.2M | $5.3M | $1.7M | $5.4M | $3.0M | $1.3M | $1.2M | $698.0K | $576.0K | $2.3M | $985.0K | $1.2M | $1.5M | $2.6M | $1.6M | $2.3M | $2.5M | $2.8M | $4.6M | $1.5M | $1.8M | $1.2M | $1.3M | $947.0K | |||||
| Unrealized Gain Loss On Investments | -$6.0K | -$11.0K | $8.0K | -$5.0K | -$6.0K | -$6.0K | $1.0K | -$10.0K | -$13.0K | $38.0K | $41.0K | $31.0K | $54.0K | -$74.0K | $4.0K | -$6.0K | -$1.0K | $13.0K | $54.0K | |||||||||||||
| Other Assets Noncurrent | $1.5M | $57.0K | $176.0K | $192.0K | $271.0K | $409.0K | $679.0K | $407.0K | $437.0K | $534.0K | $874.0K | $893.0K | $834.0K | $936.0K | $1.1M | $1.0M | $43.0K | $5.0K | $1.0M | $1.3M | $1.2M | $234.0K | $234.0K | $314.0K | $292.0K | $3.5M | ||||||
| Property Plant And Equipment Net | $148.0K | $110.0K | $125.0K | $86.0K | $96.0K | $106.0K | $98.0K | $30.0K | $70.0K | $83.0K | $110.0K | $124.0K | $694.0K | $3.6M | $3.7M | $3.8M | $4.0M | $3.7M | $1.4M | $1.0M | $883.0K | $734.0K | ||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $23.6M | -$6.7M | -$5.2M | -$2.0M | -$4.0M | -$2.8M | -$9.8M | |||||||||||||||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$6.0K | $1.0K | -$7.0K | -$2.0K | -$5.0K | $1.0K | $10.0K | $43.0K | $56.0K | $18.0K | -$23.0K | -$54.0K | -$108.0K | -$3.0K | -$7.0K | -$1.0K | ||||||||||||||||
| Liabilities | $16.6M | $17.3M | $50.9M | $48.7M | $49.9M | $42.7M | $41.2M | $19.1M | $22.1M | $22.2M | $35.8M | |||||||||||||||||||||
| Marketable Securities | $0.00 | $12.8M | $29.8M | $49.4M | $49.1M | $56.4M | $54.8M | $56.2M | $24.7M | $32.5M | $21.9M | |||||||||||||||||||||
| Repayments Of Notes Payable | $417.0K | $1.8M | $1.8M | |||||||||||||||||||||||||||||
| Accretion Amortization Of Discounts And Premiums Investments | $240.0K | $6.0K | -$103.0K | $41.0K | $46.0K | |||||||||||||||||||||||||||
| Long Term Debt Noncurrent | $22.1M | $24.1M | $26.1M | $25.9M | $2.0M | $5.3M | $6.9M | $8.6M | ||||||||||||||||||||||||
| Cash And Cash Equivalents Period Increase Decrease | -$9.8M | -$18.1M | $1.4M | -$3.3M | ||||||||||||||||||||||||||||
| Notes Payable Current | $5.0M | $4.7M | $27.8M | $4.4M | $2.2M | $7.2M | $7.2M | $7.2M | $7.2M | |||||||||||||||||||||||
| Taxes Paid Related To Net Share Settlement Of Equity Awards | $15.0K | $16.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Financing Cash Flow * | $69.4M | $51.9M | $24.7M | $7.2M | -$44.0K | $66.7M | $4.9M | $43.5M | $89.3M | $2.3M | $49.9M |
| Investing Cash Flow * | $36.2M | -$36.0M | $47.0K | $3.6M | -$162.0K | -$4.2M | -$27.7M | $24.6M | -$24.9M | ||
| Operating Cash Flow * | -$50.9M | -$30.7M | -$28.7M | -$8.2M | -$16.7M | -$18.4M | -$2.8M | -$34.5M | -$31.1M | -$29.5M | -$21.0M |
| Share Based Compensation | $6.3M | $3.1M | $3.3M | $4.0M | $4.2M | $956.0K | $36.0K | $6.9M | $4.5M | $1.3M | $1.1M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.6M | $1.4M | $849.0K | -$258.0K | -$1.2M | $263.0K | -$3.0K | $208.0K | $679.0K | $157.0K | $1.1M |
| Increase Decrease In Accrued Liabilities | $8.4M | $109.0K | $186.0K | $1.2M | -$207.0K | -$3.2M | $272.0K | $4.1M | $2.9M | $1.5M | $1.3M |
| Increase Decrease In Accounts Payable | $5.5M | $3.0M | $271.0K | $207.0K | -$294.0K | -$369.0K | $976.0K | $1.3M | $304.0K | $586.0K | $571.0K |
| Proceeds From Issuance Of Common Stock | $1.8M | $0.00 | $7.2M | $66.7M | $551.0K | $661.0K | $507.0K | $10.0K | $157.0K | ||
| Payments To Acquire Property Plant And Equipment | $116.0K | $37.0K | $88.0K | $162.0K | $2.0M | $655.0K | $525.0K | $231.0K | |||
| Proceeds From Sale And Maturity Of Marketable Securities | $93.5M | $68.5M | $43.7M | $48.1M | $35.2M | ||||||
| Payments To Acquire Marketable Securities | $51.2M | $70.7M | $70.8M | $23.0M | $59.9M | ||||||
| Increase Decrease In Deferred Grant Funding | -$23.0K | -$11.0K | -$57.0K | -$2.0K | |||||||
| Payments Of Stock Issuance Costs | $16.0K | $592.0K | $982.0K | ||||||||
| Payments Of Financing Costs | $7.4M | $1.1M | $272.0K | $106.0K | $289.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financing Cash Flow * | -$2.3M | -$8.0K | $6.0K | -$34.0K | $27.0K | $45.0K | $1.8M | -$1.8M | $5.2M | -$293.0K | ||
| Investing Cash Flow * | $36.3M | -$6.0K | $12.7M | $6.1M | -$3.7M | $3.8M | $3.0M | |||||
| Operating Cash Flow * | -$10.4M | -$6.7M | -$5.2M | -$2.0M | -$4.0M | -$2.9M | -$17.7M | -$12.7M | -$7.6M | -$6.1M | ||
| Share Based Compensation | $1.6M | $805.0K | $877.0K | $1.1M | $495.0K | $2.0K | $2.0M | $1.5M | $529.0K | $265.0K | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.6M | -$279.0K | -$91.0K | -$39.0K | -$154.0K | $275.0K | -$110.0K | $1.2M | -$19.0K | $412.0K | ||
| Increase Decrease In Accrued Liabilities | $1.7M | -$595.0K | $392.0K | -$132.0K | $145.0K | $345.0K | -$2.8M | -$293.0K | $1.9M | $1.4M | ||
| Increase Decrease In Accounts Payable | $578.0K | $261.0K | $189.0K | -$370.0K | -$34.0K | -$900.0K | -$490.0K | -$179.0K | -$1.1M | $495.0K | ||
| Proceeds From Issuance Of Common Stock | $8.0K | $6.0K | $10.0K | $248.0K | $29.0K | $41.0K | $3.0K | |||||
| Payments To Acquire Property Plant And Equipment | $61.0K | $6.0K | $133.0K | $220.0K | $53.0K | $41.0K | ||||||
| Proceeds From Sale And Maturity Of Marketable Securities | $12.7M | $27.8M | $9.1M | $13.6M | $8.3M | |||||||
| Payments To Acquire Marketable Securities | $21.6M | $12.5M | $9.7M | $5.3M | ||||||||
| Increase Decrease In Deferred Grant Funding | -$1.0K | -$3.0K | -$30.0K | |||||||||
| Payments Of Stock Issuance Costs | $107.0K | $5.1M | $46.0K | $338.0K | ||||||||
| Payments Of Financing Costs | $2.3M | $46.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$4.71 | -$12.17 | -$24.92 | -$0.80 | -$1.55 | -$6.32 | -$1.93 | -$2.44 | -$2.66 | -$15.22 | -$10.57 |
| Common Stock Shares Outstanding | 12.9M | 6.4M | 1.5M | 21.0M | 14.8M | 12.8M | 2.1M | 23.0M | 19.9M | 2.2M | |
| Common Stock Shares Issued | 12.9M | 6.4M | 1.5M | 21.0M | 14.8M | 12.8M | 2.1M | 23.0M | 19.9M | 2.2M | |
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 77.8M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Share Outstanding Basic And Diluted | 14.0M | 7.4M | 2.1M | 20.1M | 14.6M | 2.2M | 2.2M | ||||
| Earnings Per Share Basic | $-4.71 | $-12.17 | $-24.92 | $-0.80 | $-1.55 | ||||||
| Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted | 14.7M | 2.9M | 1.3M | 17.4M | |||||||
| Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic | 14.7M | 2.9M | 1.3M | 17.4M | |||||||
| Weighted Average Number Of Shares Outstanding Basic | 17.4M | 14.0M | |||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 17.4M | 14.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 | Q3 2016 | Q2 2016 | Q1 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.99 | -$0.96 | -$1.37 | -$4.54 | -$6.78 | -$4.03 | -$6.57 | -$0.42 | -$0.32 | -$0.18 | -$0.21 | -$0.17 | -$0.54 | -$0.43 | -$0.36 | -$0.45 | -$9.52 | -$0.97 | -$0.45 | -$330.00 | -$300.00 | -$0.74 | -$0.96 | -$0.02 | -$0.81 | -$0.65 | -$0.55 | -$0.50 | -$0.56 | -$4.11 | -$3.83 | -$4.09 | -$3.66 | -$3.64 |
| Common Stock Shares Outstanding | 12.5M | 12.3M | 6.6M | 1.5M | 36.4M | 36.4M | 36.3M | 21.1M | 21.0M | 21.0M | 14.8M | 14.8M | 14.8M | 14.1M | 13.5M | 11.2M | 11.2M | 23.9M | 23.9M | 23.9M | 23.2M | 20.0M | 20.0M | 19.9M | 19.8M | 19.8M | 2.2M | |||||||
| Common Stock Shares Issued | 12.5M | 12.3M | 6.6M | 1.5M | 36.4M | 36.4M | 36.3M | 21.1M | 21.0M | 21.0M | 14.8M | 14.8M | 14.8M | 14.1M | 13.5M | 11.2M | 11.2M | 23.9M | 23.9M | 23.9M | 23.2M | 20.0M | 20.0M | 19.9M | 19.8M | 19.8M | 2.2M | |||||||
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 77.8M | |||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 14.8M | 14.2M | 13.6M | 13.3M | 11.2M | 3.7M | 2.12B | 2.11B | 2.11B | 23.0M | 20.0M | 19.9M | 19.9M | 19.8M | 16.3M | 2.2M | 2.2M | 2.2M | 2.2M | |||||||||||||||
| Earnings Per Share Basic | $-0.99 | $-0.96 | $-1.37 | $-4.54 | $-6.78 | $-4.03 | $-6.57 | $-0.42 | $-0.32 | $-0.18 | $-0.21 | $-0.17 | $-0.54 | $-0.43 | ||||||||||||||||||||
| Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted | 17.8M | 11.7M | 11.4M | 1.8M | 1.8M | 1.8M | 1.5M | 21.0M | 21.0M | 18.9M | ||||||||||||||||||||||||
| Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic | 17.8M | 11.7M | 11.4M | 1.8M | 1.8M | 1.8M | 1.5M | 21.0M | 21.0M | 18.9M | ||||||||||||||||||||||||
| Weighted Average Number Of Shares Outstanding Basic | 21.0M | 21.0M | 18.9M | 14.8M | 14.8M | 14.2M | 13.6M | |||||||||||||||||||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 21.0M | 21.0M | 18.9M | 14.8M | 14.8M | 14.2M | 13.6M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $6.3M | $3.1M | $3.3M | $4.0M | $4.2M | $956.0K | $36.0K | $6.9M | $4.5M | $1.3M | $1.1M |
| Depreciation | $64.0K | $39.0K | $9.0K | $36.0K | $54.0K | $11.0K | $625.0K | $292.0K | $255.0K | $232.0K | |
| Stock Issued During Period Value Stock Options Exercised | $1.0K | $62.0K | $257.0K | $252.0K | $67.0K | $81.0K | $10.0K | $157.0K | |||
| Stock Issued During Period Value Employee Stock Purchase Plan | $18.0K | $14.0K | $16.0K | $11.0K | $299.0K | $594.0K | $426.0K | ||||
| Interest Income Other | $1.6M | $1.5M | $595.0K | $215.0K | $126.0K | ||||||
| Capital Expenditures Incurred But Not Yet Paid | $30.0K | $178.0K | $111.0K | $28.0K | |||||||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | -$29.0K | -$35.0K | -$60.0K | ||||||||
| Stock Issued During Period Value New Issues | $7.1M | $66.7M | $7.6M | $28.0M | $86.9M | ||||||
| Paid In Kind Interest | $1.7M | $1.2M | $590.0K | $570.0K | |||||||
| Fair Value Adjustment Of Warrants | -$37.0K | -$50.0K | -$111.0K | ||||||||
| Investment Income Net Amortization Of Discount And Premium | $19.0K | $9.0K | -$5.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q3 2018 | Q2 2018 | Q1 2018 | Q3 2017 | Q2 2017 | Q1 2017 | Q3 2016 | Q2 2016 | Q1 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.5M | $1.5M | $1.6M | $791.0K | $802.0K | $805.0K | $772.0K | $855.0K | $877.0K | $906.0K | $1.2M | $1.1M | $1.5M | $1.0M | $495.0K | $375.0K | $24.0K | $2.0K | $2.0K | $1.0K | $2.0K | $1.9M | $1.7M | $1.5M | ||||||
| Depreciation | $13.0K | $9.0K | $14.0K | $13.0K | $216.0K | $95.0K | $65.0K | $60.0K | ||||||||||||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $17.0K | $1.0K | $19.0K | $15.0K | $27.0K | $166.0K | $47.0K | $45.0K | $4.0K | $248.0K | $3.0K | $5.0K | $29.0K | |||||||||||||||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $9.0K | $9.0K | $6.0K | $8.0K | $9.0K | $6.0K | $11.0K | $298.0K | $290.0K | |||||||||||||||||||||
| Interest Income Other | $58.0K | $361.0K | $465.0K | $541.0K | $441.0K | $331.0K | $315.0K | $214.0K | $103.0K | $37.0K | $53.0K | $56.0K | $61.0K | |||||||||||||||||
| Capital Expenditures Incurred But Not Yet Paid | $26.0K | $45.0K | $27.0K | $109.0K | ||||||||||||||||||||||||||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | -$5.0K | -$3.0K | -$15.0K | -$7.0K | -$10.0K | -$16.0K | -$24.0K | -$24.0K | ||||||||||||||||||||||
| Stock Issued During Period Value New Issues | $7.1M | $24.0M | $9.0K | $6.1M | $1.5M | |||||||||||||||||||||||||
| Paid In Kind Interest | $654.0K | $142.0K | $147.0K | $147.0K | ||||||||||||||||||||||||||
| Fair Value Adjustment Of Warrants | $22.0K | -$59.0K | $11.0K | -$27.0K | -$2.0K | |||||||||||||||||||||||||
| Investment Income Net Amortization Of Discount And Premium | $46.0K | -$1.0K | -$3.0K |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.